Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

Thomas Brodowicz, Bernadette Liegl-Atzwager, Emmanuelle Tresch, Sophie Taieb, Andrew Kramar, Viktor Gruenwald, Marie Vanseymortier, Stéphanie Clisant, Jean-Yves Blay, Axel Le Cesne, Nicolas Penel, Thomas Brodowicz, Bernadette Liegl-Atzwager, Emmanuelle Tresch, Sophie Taieb, Andrew Kramar, Viktor Gruenwald, Marie Vanseymortier, Stéphanie Clisant, Jean-Yves Blay, Axel Le Cesne, Nicolas Penel

Abstract

Background: Angiogenesis, among other signaling pathways, plays a key-role in sarcoma biology. Regorafenib (RE) has recently been shown to be effective in imatinib and sunitinib-refractory GIST in a phase III trial.

Methods/design: We are conducting an international trial (France, Austria and Germany) consisting in 4 parallel double-blind placebo-controlled randomized (1/1) phase II trials to assess the activity and safety of RE in doxorubicin-refractory STS (ClinicalTrials.gov: NCT01900743). Each phase II trial is dedicated to one of the 4 following histological subgroups: liposarcoma, leiomyosarcoma, synovial sarcoma and other sarcoma. Within each randomized trial the following stratification factors will be applied: countries and prior exposure to pazopanib. Key-eligibility criteria are: measurable disease, age ≥18, not > 3 previous systemic treatment lines for metastatic disease, metastatic disease not amenable to surgical resection. The primary endpoint is progression-free survival (PFS) according to central radiological review. Secondary endpoints are: Toxicity (NCI-CTC AE V4.0); time to progression; Growth modulation index in pts receiving RE after randomization; 3 and 6 months PFS-Rates, best response rate and overall survival. Each phase II trial will be separately analyzed. In 3 trials, statistical assumptions are: PFS0 = 1.6 & PFS1 = 4.6 months; 1-sided α = 0.1; β = 0.05 with a total sample size of 192 pts. To take into account the rarity of synovial sarcoma, the statistical assumptions are: PFS0 = 1.6 & PFS1 = 4.6 months; 1-sided α = 0.1; β = 0.2 Tumor assessment is done monthly during the 4 first months, and every 3 months thereafter. After central radiological confirmation of tumor progression, an optional open-label option is offered to eligible patients.

Discussion: The design of this trial allows an assessment of regorafenib activity over placebo in four sarcoma strata and might provide evidence for launching a phase III trial. This study includes both integrative and exploratory translational research program. The study is enrolling since June 2013 (TRIAL REGISTRATION NUMBER: EudraCT N°: 2012-005743-24, on the 15(th) February 2012).

Figures

Figure 1
Figure 1
Trial Design: 4 parallel phase II double-blind placebo-controlled phase II trials.
Figure 2
Figure 2
Accrual at the date of 15 May 2014 (blue lines: current accrual/ red lines: theorical accrual).

References

    1. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005;10:833–41. doi: 10.1634/theoncologist.10-10-833.
    1. Penel N, Van Glabbeke M, Marreaud S, Ouali M, Hohenberger P, Blay JY. Testing new regimes in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 2011;22:1266–72. doi: 10.1093/annonc/mdq608.
    1. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188–96. doi: 10.1200/JCO.2008.21.0088.
    1. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755–63. doi: 10.1200/JCO.2006.10.4117.
    1. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol. 2009;27:3126–32. doi: 10.1200/JCO.2008.21.3223.
    1. Potti A, Ganti AK, Tendulkar K, Sholes K, Chitajallu S, Koch M, et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role in leiomyosarcoma. J Cancer Res Clin Oncol. 2004;130:52–6. doi: 10.1007/s00432-003-0504-0.
    1. Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res. 2005;25:3591–6.
    1. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: Tumor expression correlated with grade. Ann Surg Oncol. 2001;8:260–7. doi: 10.1007/s10434-001-0260-9.
    1. Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M, Kimura T. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer. 2001;84:1610–5. doi: 10.1054/bjoc.2001.1837.
    1. Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with softtissue sarcoma. J Cancer Res Clin Oncol. 1999;125:577–81. doi: 10.1007/s004320050319.
    1. Hayes AJ, Mostyn-Jones A, Koban MU, A’Hern R, Burton P, Thomas JM. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg. 2004;91:242–7. doi: 10.1002/bjs.4398.
    1. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft-tissue sarcoma. Ann Oncol. 2004;15:1261–6. doi: 10.1093/annonc/mdh309.
    1. Yoon SS, Segal NH, Park PJ, Detwiller KY, Fernando NT, Ryeom SW, et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res. 2006;135:282–90. doi: 10.1016/j.jss.2006.01.023.
    1. WT V d g, Blay JY, Chawal SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind,placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86. doi: 10.1016/S0140-6736(12)60651-5.
    1. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, et al. A phase I dose-escalation study of oral Regorafenib (BAY 73-4506), An Inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658–67. doi: 10.1158/1078-0432.CCR-11-1900.
    1. Wilhem SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kiases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–55. doi: 10.1002/ijc.25864.
    1. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12. doi: 10.1016/S0140-6736(12)61900-X.
    1. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302. doi: 10.1016/S0140-6736(12)61857-1.
    1. Cousin S, Blay JY, Bertucci F, Isambert N, Italiano A, Bompas E, et al. Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. Ann Oncol. 2013;24:2681–5. doi: 10.1093/annonc/mdt278.
    1. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23:7199–206. doi: 10.1200/JCO.2005.01.149.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅